SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Gilead Science (GILD) Followers
GILD 123.08+0.4%10:28 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (272)4/28/1997 2:51:00 PM
From: Doug Meetmer   of 961
 
That may be true certainly for the longterm, but it still takes a lot to convert all of the HIV positive patients to a triple drug regimen including the protease inhibitors. This is partly due to expense, partly due to comliance, partly due to dissemination of information to doctors and patients. For the short term, there will still be plenty of CMV patients and in addition, vistide should be able to grab market share from the other drugs used to treat CMV (such as foscarnet and gancyclovir).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News